LIVE UPDATES
Following cases of heart failure and the need for the medical space to improve on effective cardiac care, BiVACOR has successfully implanted the world's first fully mechanical heart into a human patient.
This groundbreaking achievement marks a significant boost in the treatment of heart failure and extend the lives of patients.
BiVACOR has a life-changing technology that can extend the lives of patients.
BiVACOR's Total Artificial Heart (TAH) is a state-of-the-art, titanium-crafted device, roughly the size of a human fist.
The technology device is capable of pumping blood at an impressive rate of 12 liters per minute, and ensures sufficient circulation even during physical exertion.
The tech device uses magnetically levitated rotor instead of the traditional flexible polymer diaphragms, according to Fox News.
This advanced design minimises wear and tear, potentially extending the lifespan of the device and offering a more durable solution for patients in need.
The primary objective of the BiVACOR TAH is to serve as a bridge-to-transplant solution, providing critical support for patients as they await a donor's heart.
According to the OPTN/SRTR 2022 annual data report, heart transplants in the United States have surged by 85.8% since 2011. This device could prove to be a lifesaving option for many patients in need of a transplant.
On July 9, a historic medical achievement was realised at the Texas Heart Institute, where the first human patient received the BiVACOR TAH.
This procedure, part of an FDA-approved early feasibility study, took place at Baylor St. Luke's Medical Centre within the Texas Medical Centre.
Dr. Joseph Rogers, president and CEO of the Texas Heart Institute and national principal investigator for the research, expressed his excitement, stating that the whole Texas Heart Institute is thrilled about the BiVACOR's TAH implant.
Dr. Daniel Timms, founder and CTO of BiVACOR, said, "BiVACOR's TAH is not just another mechanical heart; it represents the future of cardiac care. Utilising the same magnetic levitation technology found in high-speed rail systems, the TAH creates a frictionless environment for its single moving part.
"This cutting-edge design has the potential to outlast and outperform traditional mechanical hearts, offering a more reliable option for patients."
"Utilizing advanced maglev technology, our TAH brings us one step closer to providing a desperately needed option for people with end-stage heart failure who require support while waiting for a heart transplant."
The U.S. National Institutes of Health estimates that up to 100,000 patients could immediately benefit from mechanical circulatory support, underscoring the immense potential of this technology.
